Novo Nordisk Raises Full-Year Guidance After Strong Wegovy Pill Launch
Novo Nordisk beat expectations as its new weight-loss pill sold fast, boosting sales, prescriptions, and improving its 2026 outlook.
/ 80 items
#LLY↓
Eli Lilly Dismisses Foundayo Liver Report as 'Statistical Background Noise' — RBC Maintains Outperform
Eli Lilly states that a post-launch report of hepatic failure for Foundayo (orforglipron) is not plausibly linked to the drug. RBC Capital describes it as “statistical background noise.”
Eli Lilly Crushes Q1 Earnings and Raises 2026 Profit Forecast as Zepbound & Mounjaro Sales Explode
Eli Lilly raised profit outlook thanks to strong Zepbound & Mounjaro sales; revenue and earnings beat expectations, stock rose.
Eli Lilly Acquires Ajax Therapeutics to Advance New Treatment for Rare Blood Cancers
Eli Lilly buys Ajax to develop a new pill for rare blood cancers that may work longer and better than current treatments.
Lilly’s New Weight-Loss Pill Foundayo Gets Off to a Slow Start
Lilly’s new weight-loss pill started slow, far behind Novo’s, but it’s too early to tell which drug will win.
Lilly Buys Kelonia for Up to $7 Billion to Make CAR-T Cancer Therapy Simple and Fast
Eli Lilly buys Kelonia to develop a simpler, one-shot cancer therapy that reprograms immune cells directly inside the body.